Physician-Scientist Early Investigator and Thoracic Oncologist at the NCI. All views and tweets are my own and do not reflect those of the NIH or government.
Bethesda, Maryland
Joined December 2009
- Tweets191
- Following155
- Followers185
- Likes53
In science we depend on @FedEx to safely and quickly move reagents between labs (even during the pandemic). We have yet to receive a valuable, overnight package after 3 days. Can @FedExHelp provide some help?
New postdoctoral position is available in my laboratory to study neuroendocrine tumor immunology using novel patient-derived organoids and translational studies in upcoming clinical trials with @JaydiDelRivero tinyurl.com/j2j59w28
Excited to attend the upcoming Forbeck meeting "Neuroendocrine Cell Fate in Development and Cancer" and learn from the top experts in the field
This Post is from an account that no longer exists. Learn more
In our new paper @NatureComms we have uncovered mechanistic insights into why only a small minority of patients with relapsed small cell lung cancer respond to immunotherapy. tinyurl.com/jjkv3d3b @NCIResearchCtr @theNCI
Check out our paper taking a deep dive into EGFR mutant lung cancer resistance mechanisms in very first issue of @CellRepMed. This was translational research at its best, a collaborative effort of medical/radiation oncology, surgery and bioinformatics. cell.com/cell-reports-medici…
Nitin Roper MD retweeted
Whoo!! Our paper using multi-region phylogeny to explore the resistance mechanisms of EGFR mutant lung cancer is out! I'm really proud of the work we put into this and it's great to see it out in the world and in the very first issue of @CellRepMed
cell.com/cell-reports-medici…
MT @RamanKhannaUCSF about our @JAMAInternalMed paper. Surrogate outcomes: That’s not why we play the game wp.me/p4096x-ep
Editorial about our paper: "It’s Not Just About the Money, Money, Money." bit.ly/VPK8Cb @JAMAInternalMed @jsross119
Our paper @JAMAInternalMed Trials with industry collaboration, not industry funding, more likely to be positive bit.ly/1pYYNXv
From @NewYorker: the power of genetic sequencing to identify previously unknown medical conditions. nyr.kr/1l4oXlV
Percentage of precision cancer medicine trials in the U.S. has increased from 3% in 2006 to 16% in 2013. #ASCO14
Nitin Roper MD retweeted
Percentage of #precisionmedicine trials in the U.S. has increased from 3% in 2006 to 16% in 2013. Roper et al. Abstract number 1547 #LCI
Future of precision cancer medicine will be large clinical registries such as Cancer LinQ, not randomized trials. - Dr. Schilsky #ASCO14
How Germany, unlike the U.S., creates a competitive market for prescription drugs. bit.ly/1pgZ1Hd
Nitin Roper MD retweeted
FDA to Put Almost $38 Million Behind Effort to Improve Clinical Trials raps.org/focus-online/news/n…
Nitin Roper MD retweeted
Progress Against GI Cancer During @ASCO First 50 Years. m.jco.ascopubs.org/content/e… #cancer #pancreaticcancer #coloncancer
Nitin Roper MD retweeted
The end of tamiflu. The beginning of trials transparency? My BIG PIECE in the Guardian today #AllTrials
gu.com/p/3zat8
Nitin Roper MD retweeted
Handwashing is a more effective flu prophylactic than Tamiflu, says Cochrane review scripintelligence.com/home/U…